The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.

This module will present current and new clinical data of targeted therapies and how this information translates into personalized medicine and the development of individualized treatment plans for patients with NSCLC based on expression of biomarkers.

It is essential that all members of the NSCLC care team understand the necessary processes and are equipped to apply current research on genomic targets to testing for mutations/drivers in appropriate advanced NSCLC patients.

As a result of the therapeutic advances and clinical research affecting the management of patients with non-small cell lung cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.

Many patients with stages I to IIIA NSCLC are eligible for surgery followed by adjuvant therapy. Multidisciplinary evaluation is recommended to decide whether patients with stages I to IIIA NSCLC have resectable disease and to determine the most appropriate surgical procedure. The NCCN Guidelines now recommend biomarker testing for EGFR mutations in patients with completely resected stages IB to IIIA NSCLC to determine whether they are eligible for certain adjuvant targeted therapy. Previously, the NCCN Guidelines only recommended biomarker testing for eligible patients with advanced NSCLC.

This tumor board will discuss how to select the most appropriate therapy for patients with non-small cell lung cancer (NSCLC) using a case-based format. New targeted therapy regimens are being rapidly approved for patients with metastatic NSCLC and have been shown to improve outcomes for these patients.

This activity will address the increasing use of biomarker testing in the management of patients with non-small cell lung cancer, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.